BCR-ABL+ acute myeloid leukemia: are we always dealing with a high-risk disease?

• Nina Rosa Neuendorff,
• Philipp Hemmati,
• Renate Arnold,
• Jana Ihlow,
• Bernd Dörken,
• Carsten Müller-Tidow,
• Jörg Westermann

Affiliations

Nina Rosa Neuendorff

Department of Hematology, Oncology and Tumor Immunology, Campus Virchow Klinik, Charité University Medicine, Berlin, Germany;; Department of Hematology, Oncology and Rheumatology, Heidelberg University Hospital, Heidelberg, Germany; Nina Rosa Neuendorff, Department of Hematology, Oncology and Rheumatology, Heidelberg University Hospital, Im Neuenheimer Feld 410, D-69120 Heidelberg, Germany

Philipp Hemmati

Department of Hematology, Oncology and Tumor Immunology, Campus Virchow Klinik, Charité University Medicine, Berlin, Germany;

Renate Arnold

Department of Hematology, Oncology and Tumor Immunology, Campus Virchow Klinik, Charité University Medicine, Berlin, Germany;

Jana Ihlow

Department of Hematology, Oncology and Tumor Immunology, Campus Virchow Klinik, Charité University Medicine, Berlin, Germany;

Bernd Dörken

Department of Hematology, Oncology and Tumor Immunology, Campus Virchow Klinik, Charité University Medicine, Berlin, Germany;

Carsten Müller-Tidow

Department of Hematology, Oncology and Rheumatology, Heidelberg University Hospital, Heidelberg, Germany

Jörg Westermann

Department of Hematology, Oncology and Tumor Immunology, Campus Virchow Klinik, Charité University Medicine, Berlin, Germany;